Edition:
United States

Novo Nordisk A/S (NOVOb.CO)

NOVOb.CO on Copenhagen Stock Exchange

303.70DKK
10:59am EDT
Change (% chg)

kr.-1.85 (-0.61%)
Prev Close
kr.305.55
Open
kr.305.20
Day's High
kr.307.50
Day's Low
kr.303.70
Volume
2,118,920
Avg. Vol
3,094,947
52-wk High
kr.354.80
52-wk Low
kr.260.20

Select another date:

Wed, May 23 2018

BRIEF-Epigen Biosciences Says Enters Collaboration Agreement With Novo Nordisk A/S

* EPIGEN BIOSCIENCES SAYS ENTERS COLLABORATION TO LICENSE ITS LPA1 RECEPTOR SMALL MOLECULE PROGRAM TO NOVO NORDISK A/S FOR UP TO USD 200 MILLION

BRIEF-Novo Nordisk Says Initiated New Share Repurchase Programme For Up To Dkk 2.7 Billion

* AS PART OF UPTO DKK 14 BILLION 2018 SHARE REPURCHASE PROGRAMME, CO INITIATED NEW SHARE REPURCHASE PROGRAMME FOR AN AMOUNT OF UP TO DKK 2.7 BILLION

BRIEF-Novo Nordisk A/S purchases B Shares worth Dkk 1,038 Mln from Novo Holdings A/S under 2018 share repurchase programme

* NOVO NORDISK A/S PURCHASES B SHARES WORTH DKK 1,038 MILLION FROM NOVO HOLDINGS A/S UNDER THE 2018 SHARE REPURCHASE PROGRAMME

Novo Nordisk upbeat on new diabetes drug as profit tops forecast

COPENHAGEN Novo Nordisk , the world's biggest maker of diabetes drugs, reported a smaller than expected fall in first-quarter profit and nudged up its full-year forecast as sales of new medicines helped to soften the hit from a weaker U.S. dollar.

UPDATE 2-Novo Nordisk upbeat on new diabetes drug as profit tops forecast

* U.S. legislation puts pressure on 2019 sales (Adds CEO quotes, share price)

BRIEF-Novo Nordisk CEO: New Ozempic Drug To Reach At Least DKK 1 Billion Sales In 2018

May 2 NOVO NORDISK A/S CEO LARS FRUERGAARD JORGENSEN SAID AT CALL AFTER Q1 EARNINGS:

Drugmaker Novo Nordisk beats Q1 profit expectations, nudges up 2018 outlook

COPENHAGEN, May 2 Denmark's Novo Nordisk , the world's biggest maker of diabetes drugs, posted a posted first-quarter operating profit above expectations on Wednesday and lifted the lower end of its 2018 sales and profit outlook.

BRIEF-Novo Nordisk Beats Q1 Expectations; Lifts 2018 Guidance A Tad

* OPERATING PROFIT DECREASED BY 8% IN DANISH KRONER AND INCREASED BY 6% IN LOCAL CURRENCIES IN THE FIRST THREE MONTHS OF 2018

BRIEF-Novo Nordisk Investigates Hypoglycaemia's Impact On Diabetes

* PARTICIPATES IN NEW RESEARCH PROJECT HYPO-RESOLVE TO INVESTIGATE HYPOGLYCAEMIA AND ITS IMPACT IN DIABETES

BRIEF-Emisphere Technologies Amended Its Existing 2015 Development And License Agreement With Novo Nordisk

* EMISPHERE TECHNOLOGIES INC - AMENDED ITS EXISTING 2015 DEVELOPMENT AND LICENSE AGREEMENT WITH NOVO NORDISK A/S

Select another date: